Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
Status:
NOT_YET_RECRUITING
Trial end date:
2025-04-10
Target enrollment:
Participant gender:
Summary
This study aims to compare the efficacy and safety of Sacubitril/Valsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period, including two treatment groups, with a total of 297 eligible subjects randomly assigned in a 2:1 ratio to either the experimental group or the control group.Subjects will participate in the study through two phases: the screening period and the follow-up period.The primary outcome measure is the change in systolic blood pressure from baseline after 12 weeks of treatment.
Phase:
PHASE4
Details
Lead Sponsor:
Sichuan Academy of Medical Sciences
Collaborators:
Chengdu First People's Hospital Dazhou Central Hospital Guan'an People's Hospital Meishan People's Hospital Meishan Traditional Chinese Medicine Hospital Mianyang People's Hospital Nanchong Central Hospital Qijiang District People's Hospital The Affiliated Traditional Chinese Medicine Hospital Of Southwest Medical University The First People's Hospital of Guangyuan The People's Hospital of Leshan The Second Affiliated Hospital of Chongqing Medical University
Treatments:
sacubitril and valsartan sodium hydrate drug combination Valsartan